APOE; Alzheimer's disease; TREM2; amyloid beta; astrocytes; biomarkers; dementia; inflammation; microglia; neurodegeneration; neuroglia; neuroinflammation; tau; Apolipoproteins E; Humans; Microglia/pathology; Inflammation; Apolipoproteins E/genetics; Alzheimer Disease/pathology; Epidemiology; Health Policy; Developmental Neuroscience; Neurology (clinical); Geriatrics and Gerontology; Cellular and Molecular Neuroscience; Psychiatry and Mental Health
Abstract :
[en] [en] INTRODUCTION: At the Alzheimer's Association's APOE and Immunity virtual conference, held in October 2021, leading neuroscience experts shared recent research advances on and inspiring insights into the various roles that both the apolipoprotein E gene (APOE) and facets of immunity play in neurodegenerative diseases, including Alzheimer's disease and other dementias.
METHODS: The meeting brought together more than 1200 registered attendees from 62 different countries, representing the realms of academia and industry.
RESULTS: During the 4-day meeting, presenters illuminated aspects of the cross-talk between APOE and immunity, with a focus on the roles of microglia, triggering receptor expressed on myeloid cells 2 (TREM2), and components of inflammation (e.g., tumor necrosis factor α [TNFα]).
DISCUSSION: This manuscript emphasizes the importance of diversity in current and future research and presents an integrated view of innate immune functions in Alzheimer's disease as well as related promising directions in drug development.
Precision for document type :
Review article
Disciplines :
Life sciences: Multidisciplinary, general & others Neurology
Author, co-author :
Kloske, Courtney M; Alzheimer's Association, Chicago, Illinois, USA
Barnum, Christopher J; INmune Bio, Inc, La Jolla, California, USA
Batista, Andre F; Department of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA ; Departments of Neurology, Harvard Medical School, Boston, Massachusetts, USA
Bradshaw, Elizabeth M; Department of Neurology, Columbia University Irving Medical Center, New York, New York, USA
Brickman, Adam M; Taub Institute for Research on Alzheimer's Disease and the Aging Brain, G.H. Sergievsky Center, and Department of Neurology, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA
Bu, Guojun; Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA
Dennison, Jessica; Department of Psychiatry & Behavioral Sciences, University of Miami Miller School of Medicine, Miami, Florida, USA
Gearon, Mary D; Department of Physiology, University of Kentucky, Lexington, Kentucky, USA
Goate, Alison M; Department of Genetics & Genomic Sciences, Ronald M. Loeb Center for Alzheimer's disease, Icahn School of Medicine at Mount Sinai, New York, New York, USA
Haass, Christian; Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, LMU Munich, Munich, Germany ; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany 3 Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
HENEKA, Michael ; University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB)
Hu, William T; Department of Neurology, Rutgers-Robert Wood Johnson Medical School and Center for Healthy Aging, Rutgers Institute for Health, Health Care Policy, and Aging Research, New Brunswick, New Jersey, USA
Huggins, Lenique K L; Department of Biology, Duke University, Durham, North Carolina, USA ; Yale School of Medicine, New Haven, Connecticut, USA
Jones, Nahdia S; Interdisciplinary Program in Neuroscience, Georgetown University, Washington, District of Columbia, USA
Koldamova, Radosveta; EOH, School of Public Health University of Pittsburgh, Pittsburgh, Pennsylvania, USA
Lemere, Cynthia A; Department of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA ; Departments of Neurology, Harvard Medical School, Boston, Massachusetts, USA
Liddelow, Shane A; Neuroscience Institute and Departments of Neuroscience & Physiology and of Ophthalmology, NYU Grossman School of Medicine, New York, New York, USA
Marcora, Edoardo; Ronald M. Loeb Center for Alzheimer's disease, Dept. of Genetics & Genomic Sciences, Dept. of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York, USA
Marsh, Samuel E; F.M. Kirby Neurobiology Center, Boston Children's Hospital, Boston, Massachusetts, USA ; Harvard Medical School, Boston, Massachusetts, USA ; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA
Nielsen, Henrietta M; Department of Biochemistry and Biophysics, Stockholm University, Stockholm, Sweden
Petersen, Kellen K; The Saul R. Korey Department of Neurology, Albert Einstein College of Medicine, Bronx, New York, USA
Petersen, Melissa; Department of Family Medicine, Institute of Translational Research, University of North Texas Health Science Center, Fort Worth, Texas, USA
Piña-Escudero, Stefanie D; Global Brain Health Institute, Department of Neurology, University of California, San Francisco, California, USA
Qiu, Wei Qiao; Boston University School of Medicine, Boston, Massachusetts, USA
Quiroz, Yakeel T; Departments of Psychiatry and Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
Reiman, Eric; Banner Alzheimer's Institute, Phoenix, Arizona, USA ; Banner Research, Phoenix, Arizona, USA
Sexton, Claire ; Alzheimer's Association, Chicago, Illinois, USA
Tansey, Malú Gámez; Department of Neuroscience and Center for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, Florida, USA
Tcw, Julia; Department of Pharmacology & Experimental Therapeutics, Boston University School of Medicine, Boston, Massachusetts, USA
Teunissen, Charlotte E; Neurochemistry Laboratory, Clinical Chemistry department, Amsterdam Neuroscience, Program Neurodegeneration, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
Tijms, Betty M; Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands ; Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands
van der Kant, Rik; Department of Functional Genomics, Center for Neurogenomics and Cognitive Research (CNCR), VU University Amsterdam, Amsterdam, The Netherlands ; Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Amsterdam University Medical Center, Amsterdam, The Netherlands
Wallings, Rebecca; CTRND, Department of Neuroscience, University of Florida, Florida, USA
Weninger, Stacie C; FBRI, Cambridge, Massachusetts, USA
Wharton, Whitney; School of Nursing, EmoryUniversity, Atlanta, Georgia, USA
Wilcock, Donna M; Sanders-Brown Center on Aging and Department of Physiology, University of Kentucky, Lexington, Kentucky, USA
Wishard, Tyler James; Psychiatry & Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, California, USA
Worley, Susan L; Independent science writer, Bryn Mawr, Pennsylvania, USA
Zetterberg, Henrik; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden ; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden ; Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK ; UK Dementia Research Institute at UCL, London, UK ; Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong, China
Carrillo, Maria C; Alzheimer's Association, Chicago, Illinois, USA
Alzheimer's and Dementia: the Journal of the Alzheimer's Association
ISSN :
1552-5260
eISSN :
1552-5279
Publisher :
John Wiley and Sons Inc, United States
Volume :
19
Issue :
6
Pages :
2677 - 2696
Peer reviewed :
Peer Reviewed verified by ORBi
Funding text :
The authors would like to thank and acknowledge all conference organizers, speakers, and session chairs for your tremendous contributions to this conference. The authors would also like to thank Joanna Graca at the Alzheimer's Association for her work on this article. Courtney M. Kloske is a full-time employee of the Alzheimer's Association. Christopher J. Barnum reports in the past 36 months, grants or contracts from Alzheimer's Association, ALS Association, and the National Institutes of Health (NIH); and holds multiple patents surrounding treating neurodegenerative disease with TNF inhibitors. Andre F. Batista has nothing to disclose. Elizabeth M. Bradshaw reports in the past 36 months, grants or contracts from NIH/National Institutes on Aging (NIA) 1RF1AG058852 04/15/2018 – 03/31/2023 Bradshaw, Parkinson's Disease Foundation PF-RCE-1948 07/01/2019 – 06/30/2023 Przedborski, NIH/NIA 5R01AG067581 05/15/2020 – 01/31/2025 Bradshaw/Elyaman, NIH/NIA 5U01AG061356 09/30/2018 – 08/31/2023 Bennett/De Jager, NIH/NIA 1R21AG073882 08/15/2021 – 07/31/2023 Bradshaw, NIH/NIA 5R01AG076018 09/30/2021 – 05/31/2026 Bradshaw/Elyaman/Vardarajan, IDSA CU21-3089 01/24/2022 – 12/24/2022 Bradshaw, CZI 2021-235054 07/01/2021 – 06/30/2022 Bradshaw/Jiang; patents 2020 Rui Chang, Wassim Elyaman, Elizabeth Bradshaw, Patrick Ronaldson, Kuixi Zhu, Qianying He Compositions and Methods for Treating Neurodegenerative Disorders with NADH and/or PEITC US 63/071,032; 2021 Elizabeth Bradshaw, Wassim Elyaman Compositions and Methods for the Treatment of Alzheimer's Disease 88800730-000443.
Thal DR, Walter J, Saido TC, Fändrich M. Neuropathology and biochemistry of Aβ and its aggregates in Alzheimer's disease. Acta Neuropathol (Berl). 2015;129:167-182. doi:10.1007/s00401-014-1375-y
Braak H, Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging. 1995;16:271-278. doi:10.1016/0197-4580(95)00021-6. discussion 278-284.
Jack CR, Bennett DA, Blennow K, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement J Alzheimers Assoc. 2018;14:535-562. doi:10.1016/j.jalz.2018.02.018
Lanoiselée H-M, Nicolas G, Wallon D, et al. APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: a genetic screening study of familial and sporadic cases. PLoS Med. 2017;14:e1002270. doi:10.1371/journal.pmed.1002270
Wu L, Rosa-Neto P, Hsiung G-YR, et al. Early-onset familial Alzheimer's disease (EOFAD). Can J Neurol Sci J Can Sci Neurol. 2012;39:436-445. doi:10.1017/s0317167100013949
Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921-923. doi:10.1126/science.8346443
Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA. 1993;90:1977-1981. doi:10.1073/pnas.90.5.1977
Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 1993;43:1467-1472. doi:10.1212/wnl.43.8.1467
Shi Y, Holtzman DM. Interplay between innate immunity and Alzheimer disease: aPOE and TREM2 in the spotlight. Nat Rev Immunol. 2018;18:759-772. doi:10.1038/s41577-018-0051-1
Kloske CM, Dugan AJ, Weekman EM, et al. Inflammatory pathways are impaired in Alzheimer disease and differentially associated With apolipoprotein E status. J Neuropathol Exp Neurol. 2021;80:922-932. doi:10.1093/jnen/nlab085
Mahley RW. Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders. J Mol Med Berl Ger. 2016;94:739-746. doi:10.1007/s00109-016-1427-y
Chen Y, Strickland MR, Soranno A, Holtzman DM. Apolipoprotein E: structural insights and links to Alzheimer disease pathogenesis. Neuron. 2021;109:205-221. doi:10.1016/j.neuron.2020.10.008
de Chaves EP, Narayanaswami V. Apolipoprotein E and cholesterol in aging and disease in the brain. Future Lipidol. 2008;3:505-530. doi:10.2217/17460875.3.5.505
Phillips MC. Apolipoprotein E isoforms and lipoprotein metabolism. IUBMB Life. 2014;66:616-623. doi:10.1002/iub.1314
Qian J, Wolters FJ, Beiser A, et al. APOE-related risk of mild cognitive impairment and dementia for prevention trials: an analysis of four cohorts. PLoS Med. 2017;14:e1002254. doi:10.1371/journal.pmed.1002254
Garatachea N, Emanuele E, Calero M, et al. ApoE gene and exceptional longevity: insights from three independent cohorts. Exp Gerontol. 2014;53:16-23. doi:10.1016/j.exger.2014.02.004
Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS. J Lipid Res. 2009;50:S183-S188. doi:10.1194/jlr.R800069-JLR200. Suppl.
Rhea EM, Raber J, Banks WA. ApoE and cerebral insulin: trafficking, receptors, and resistance. Neurobiol Dis. 2020;137:104755. doi:10.1016/j.nbd.2020.104755
Zhao N, Liu C-C, Van Ingelgom AJ, et al. Apolipoprotein E4 impairs neuronal insulin signaling by trapping insulin receptor in the endosomes. Neuron. 2017;96:115-129. doi:10.1016/j.neuron.2017.09.003. e5.
Jagust WJ, Landau SM. Initiative F the ADN. Apolipoprotein E, not fibrillar β-amyloid, reduces cerebral glucose metabolism in normal aging. J Neurosci. 2012;32:18227-18233. doi:10.1523/JNEUROSCI.3266-12.2012
Wu L, Zhang X, Zhao L. Human ApoE isoforms differentially modulate brain glucose and ketone body metabolism: implications for Alzheimer's disease risk reduction and early intervention. J Neurosci Off J Soc Neurosci. 2018;38:6665-6681. doi:10.1523/JNEUROSCI.2262-17.2018
Walker JM, Harrison FE. Shared neuropathological characteristics of obesity, Type 2 diabetes and Alzheimer's disease: impacts on cognitive decline. Nutrients. 2015;7:7332-7357. doi:10.3390/nu7095341
Mosconi L, Rinne JO, Tsui WH, et al. Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer's parents. Neurobiol Aging. 2013;34:22-34. doi:10.1016/j.neurobiolaging.2012.03.002
Burns CM, Kaszniak AW, Chen K, et al. Longitudinal changes in serum glucose levels are associated with metabolic changes in Alzheimer's disease related brain regions. J Alzheimers Dis JAD. 2018;62:833-840. doi:10.3233/JAD-170767
Bangen KJ, Himali JJ, Beiser AS, et al. Interaction between midlife blood glucose and APOE genotype predicts later Alzheimer's disease pathology. J Alzheimers Dis JAD. 2016;53:1553-1562. doi:10.3233/JAD-160163
Nielsen HM, Chen K, Lee W, et al. Peripheral apoE isoform levels in cognitively normal APOE ε3/ε4 individuals are associated with regional gray matter volume and cerebral glucose metabolism. Alzheimers Res Ther. 2017;9:5. doi:10.1186/s13195-016-0231-9
Edlund AK, Chen K, Lee W, et al. Plasma apolipoprotein E3 and glucose levels are associated in APOE ɛ3/ɛ4 carriers. J Alzheimers Dis JAD. 2021;81:339-354. doi:10.3233/JAD-210065
Yarchoan M, Louneva N, Xie SX, et al. Association of plasma C-reactive protein levels with the diagnosis of Alzheimer's disease. J Neurol Sci. 2013;333:9-12. doi:10.1016/j.jns.2013.05.028
Wang Y, Grydeland H, Roe JM, et al. Associations of circulating C-reactive proteins, APOE ε4, and brain markers for Alzheimer's disease in healthy samples across the lifespan. Brain Behav Immun. 2022;100:243-253. doi:10.1016/j.bbi.2021.12.008
Association of Chronic Low-grade Inflammation With Risk of Alzheimer Disease in ApoE4 Carriers | Dementia and Cognitive Impairment | JAMA Network Open | JAMA Network n.d. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2707427 (accessed November 30, 2022)
Tao Q, Alvin Ang TF, Akhter-Khan SC, et al. Impact of C-reactive protein on cognition and Alzheimer disease biomarkers in homozygous apolipoprotein E ɛ4 carriers. Neurology. 2021. doi:10.1212/WNL.0000000000012512
Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015;14:388-405. doi:10.1016/S1474-4422(15)70016-5
Henstridge CM, Tzioras M, Paolicelli RC. Glial contribution to excitatory and inhibitory synapse loss in neurodegeneration. Front Cell Neurosci. 2019;13:63. doi:10.3389/fncel.2019.00063
Brosseron F, Krauthausen M, Kummer M, Heneka MT. Body fluid cytokine levels in mild cognitive impairment and Alzheimer's disease: a comparative overview. Mol Neurobiol. 2014;50:534-544. doi:10.1007/s12035-014-8657-1
Morgan AR, Touchard S, Leckey C, et al. Inflammatory biomarkers in Alzheimer's disease plasma. Alzheimers Dement J Alzheimers Assoc. 2019;15:776-787. doi:10.1016/j.jalz.2019.03.007
Edison P, Donat CK, Sastre M. In vivo imaging of glial activation in Alzheimer's disease. Front Neurol. 2018;9:625. doi:10.3389/fneur.2018.00625
Dani M, Wood M, Mizoguchi R, et al. Microglial activation correlates in vivo with both tau and amyloid in Alzheimer's disease. Brain. 2018;141:2740-2754. doi:10.1093/brain/awy188
Konijnenberg E, Tijms BM, Gobom J, et al. APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease. Alzheimers Res Ther. 2020;12:65. doi:10.1186/s13195-020-00628-z
Sudduth TL, Schmitt FA, Nelson PT, Wilcock DM. Neuroinflammatory phenotype in early Alzheimer's disease. Neurobiol Aging. 2013;34:1051-1059. doi:10.1016/j.neurobiolaging.2012.09.012
Kloske CM, Wilcock DM. The important interface between apolipoprotein E and neuroinflammation in Alzheimer's disease. Front Immunol. 2020;11:754. doi:10.3389/fimmu.2020.00754
Rea IM, Gibson DS, McGilligan V, McNerlan SE, Alexander HD, Ross OA. Age and age-related diseases: role of inflammation triggers and cytokines. Front Immunol. 2018;9:586. doi:10.3389/fimmu.2018.00586
Guttenplan KA, Weigel MK, Prakash P, et al. Neurotoxic reactive astrocytes induce cell death via saturated lipids. Nature. 2021;599:102-107. doi:10.1038/s41586-021-03960-y
Marsh SE, Abud EM, Lakatos A, et al. The adaptive immune system restrains Alzheimer's disease pathogenesis by modulating microglial function. Proc Natl Acad Sci U S A. 2016;113:E1316-E1325. doi:10.1073/pnas.1525466113
Kim K, Wang X, Ragonnaud E, et al. Therapeutic B-cell depletion reverses progression of Alzheimer's disease. Nat Commun. 2021;12:2185. doi:10.1038/s41467-021-22479-4
Cugurra A, Mamuladze T, Rustenhoven J, et al. Skull and vertebral bone marrow are myeloid cell reservoirs for the meninges and CNS parenchyma. Science. 2021;373:eabf7844. doi:10.1126/science.abf7844
Brioschi S, Wang W-L, Peng V, et al. Heterogeneity of meningeal B cells reveals a lymphopoietic niche at the CNS borders. Science. 2021;373:eabf9277. doi:10.1126/science.abf9277
Chan WY, Kohsaka S, Rezaie P. The origin and cell lineage of microglia: new concepts. Brain Res Rev. 2007;53:344-354. doi:10.1016/j.brainresrev.2006.11.002
Vance RE, Isberg RR, Portnoy DA. Patterns of pathogenesis: discrimination of pathogenic and nonpathogenic microbes by the innate immune system. Cell Host Microbe. 2009;6:10-21. doi:10.1016/j.chom.2009.06.007
Condello C, Yuan P, Schain A, Grutzendler J. Microglia constitute a barrier that prevents neurotoxic protofibrillar Aβ42 hotspots around plaques. Nat Commun. 2015;6:6176. doi:10.1038/ncomms7176
Houtman J, Freitag K, Gimber N, Schmoranzer J, Heppner FL, Jendrach M. Beclin1-driven autophagy modulates the inflammatory response of microglia via NLRP3. EMBO J. 2019;38:e99430. doi:10.15252/embj.201899430
Liddelow SA, Guttenplan KA, Clarke LE, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541:481-487. doi:10.1038/nature21029
Barbar L, Jain T, Zimmer M, et al. CD49f is a novel marker of functional and reactive human iPSC-derived astrocytes. Neuron. 2020;107:436-453. doi:10.1016/j.neuron.2020.05.014. e12.
Butovsky O, Jedrychowski MP, Moore CS, et al. Identification of a unique TGF-β-dependent molecular and functional signature in microglia. Nat Neurosci. 2014;17:131-143. doi:10.1038/nn.3599
Keren-Shaul H, Spinrad A, Weiner A, et al. A unique microglia type associated with restricting development of Alzheimer's disease. Cell. 2017;169:1276-1290. doi:10.1016/j.cell.2017.05.018. e17.
Nugent AA, Lin K, van Lengerich B, et al. TREM2 regulates microglial cholesterol metabolism upon chronic phagocytic challenge. Neuron. 2020;105:837-854. doi:10.1016/j.neuron.2019.12.007. e9.
Parhizkar S, Arzberger T, Brendel M, et al. Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE. Nat Neurosci. 2019;22:191-204. doi:10.1038/s41593-018-0296-9
Lewcock JW, Schlepckow K, Di Paolo G, Tahirovic S, Monroe KM, Haass C. Emerging microglia biology defines novel therapeutic approaches for Alzheimer's disease - ScienceDirect 2020. Neuron. 2020;108:801-821. https://www.sciencedirect.com/science/article/pii/S0896627320307534. accessed May 31, 2022.
Ransohoff RM. A polarizing question: do M1 and M2 microglia exist? Nat Neurosci. 2016;19:987-991. doi:10.1038/nn.4338
Nott A, Holtman IR, Coufal NG, et al. Brain cell type-specific enhancer-promoter interactome maps and disease-risk association. Science. 2019;366:1134-1139. doi:10.1126/science.aay0793
Abud EM, Ramirez RN, Martinez ES, et al. iPSC-derived human microglia-like cells to study neurological diseases. Neuron. 2017;94:278-293. doi:10.1016/j.neuron.2017.03.042. e9.
Marsh SE, Walker AJ, Kamath T, et al. Dissection of artifactual and confounding glial signatures by single-cell sequencing of mouse and human brain. Nat Neurosci. 2022;25:306-316. doi:10.1038/s41593-022-01022-8
Foo LC, Allen NJ, Bushong EA, et al. Development of a method for the purification and culture of rodent astrocytes. Neuron. 2011;71:799-811. doi:10.1016/j.neuron.2011.07.022
Masuda T, Sankowski R, Staszewski O, et al. Spatial and temporal heterogeneity of mouse and human microglia at single-cell resolution. Nature. 2019;566:388-392. doi:10.1038/s41586-019-0924-x
Zhou Y, Song WM, Andhey PS, et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease. Nat Med. 2020;26:131-142. doi:10.1038/s41591-019-0695-9
Kamath T, Abdulraouf A, Burris SJ, et al. Single-cell genomic profiling of human dopamine neurons identifies a population that selectively degenerates in Parkinson's disease. Nat Neurosci. 2022;25:588-595. doi:10.1038/s41593-022-01061-1
Bohlen CJ, Bennett FC, Tucker AF, Collins HY, Mulinyawe SB, Barres BA. Diverse requirements for microglial survival, specification, and function revealed by defined-medium cultures. Neuron. 2017;94:759-773. doi:10.1016/j.neuron.2017.04.043. e8.
Gosselin D, Skola D, Coufal NG, et al. An environment-dependent transcriptional network specifies human microglia identity. Science. 2017;356:eaal3222. doi:10.1126/science.aal3222
Bennett ML, Bennett FC, Liddelow SA, et al. New tools for studying microglia in the mouse and human CNS. Proc Natl Acad Sci USA. 2016;113:E1738-E1746. doi:10.1073/pnas.1525528113
Hasel P, Rose IVL, Sadick JS, Kim RD, Liddelow SA. Neuroinflammatory astrocyte subtypes in the mouse brain. Nat Neurosci. 2021;24:1475-1487. doi:10.1038/s41593-021-00905-6
Bayraktar OA, Bartels T, Holmqvist S, et al. Astrocyte layers in the mammalian cerebral cortex revealed by a single-cell in situ transcriptomic map. Nat Neurosci. 2020;23:500-509. doi:10.1038/s41593-020-0602-1
Hammond TR, Dufort C, Dissing-Olesen L, et al. Single-cell RNA sequencing of microglia throughout the mouse lifespan and in the injured brain reveals complex cell-state changes. Immunity. 2019;50:253-271. doi:10.1016/j.immuni.2018.11.004. e6.
Sadick JS, O'Dea MR, Hasel P, Dykstra T, Faustin A, Liddelow SA. Astrocytes and oligodendrocytes undergo subtype-specific transcriptional changes in Alzheimer's disease. Neuron. 2022;110:1788-1805. doi:10.1016/j.neuron.2022.03.008. e10.
Mathys H, Davila-Velderrain J, Peng Z, et al. Single-cell transcriptomic analysis of Alzheimer's disease. Nature. 2019;570:332-337. doi:10.1038/s41586-019-1195-2
Li R, Wang X, He P. The most prevalent rare coding variants of TREM2 conferring risk of Alzheimer's disease: a systematic review and meta-analysis. Exp Ther Med. 2021;21:347. doi:10.3892/etm.2021.9778
Fitz NF, Nam KN, Wolfe CM, et al. Phospholipids of APOE lipoproteins activate microglia in an isoform-specific manner in preclinical models of Alzheimer's disease. Nat Commun. 2021;12:3416. doi:10.1038/s41467-021-23762-0
Fitz NF, Wolfe CM, Playso BE, et al. Trem2 deficiency differentially affects phenotype and transcriptome of human APOE3 and APOE4 mice. Mol Neurodegener. 2020;15:41. doi:10.1186/s13024-020-00394-4
Giannisis A, Al-Grety A, Carlsson H, et al. Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimer's disease. Alzheimers Res Ther. 2022;14:115. doi:10.1186/s13195-022-01058-9
Lautner R, Insel PS, Skillbäck T, et al. Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations. Alzheimers Res Ther. 2017;9:87. doi:10.1186/s13195-017-0313-3
Lautner R, Palmqvist S, Mattsson N, et al. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. JAMA Psychiatry. 2014;71:1183-1191. doi:10.1001/jamapsychiatry.2014.1060
Apostolova LG, Hwang KS, Kohannim O, et al. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease. NeuroImage Clin. 2014;4:461-472. doi:10.1016/j.nicl.2013.12.012
Tijms BM, Gobom J, Reus L, et al. Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics. Brain J Neurol. 2020;143:3776-3792. doi:10.1093/brain/awaa325
Hu WT, Ozturk T, Kollhoff A, Wharton W, Christina Howell J. Higher CSF sTNFR1-related proteins associate with better prognosis in very early Alzheimer's disease. Nat Commun. 2021;12:4001. doi:10.1038/s41467-021-24220-7
Wolters FJ, Yang Q, Biggs ML, et al. The impact of APOE genotype on survival: results of 38,537 participants from six population-based cohorts (E2-CHARGE). PLoS ONE. 2019;14:e0219668. doi:10.1371/journal.pone.0219668
Appiah F, Charnigo RJ. A comparison of methods for predicting future cognitive status: mixture modeling, latent class analysis, and competitors. Alzheimer Dis Assoc Disord. 2021;35:306-314. doi:10.1097/WAD.0000000000000462
Robinson AC, Davidson YS, Roncaroli F, et al. Influence of APOE genotype on mortality and cognitive impairment. J Alzheimers Dis Rep. 2020;4:281-286. doi:10.3233/ADR-200203
Abondio P, Sazzini M, Garagnani P, et al. The genetic variability of APOE in different human populations and its implications for longevity. Genes. 2019;10:222. doi:10.3390/genes10030222
Granot-Hershkovitz E, Tarraf W, Kurniansyah N, et al. APOE alleles’ association with cognitive function differs across Hispanic/Latino groups and genetic ancestry in the study of Latinos-investigation of neurocognitive aging (HCHS/SOL). Alzheimers Dement. 2021;17:466-474. doi:10.1002/alz.12205
Schindler SE, Cruchaga C, Joseph A, et al. African Americans have differences in CSF soluble TREM2 and associated genetic variants. Neurol Genet. 2021;7:e571. doi:10.1212/NXG.0000000000000571
Ferretti MT, Iulita MF, Cavedo E, et al. Sex differences in Alzheimer disease - the gateway to precision medicine. Nat Rev Neurol. 2018;14:457-469. doi:10.1038/s41582-018-0032-9
Mazure CM, Swendsen J. Sex differences in Alzheimer's disease and other dementias. Lancet Neurol. 2016;15:451-452. doi:10.1016/S1474-4422(16)00067-3
Kodama L, Guzman E, Etchegaray JI, et al. Microglial microRNAs mediate sex-specific responses to tau pathology. Nat Neurosci. 2020;23:167-171. doi:10.1038/s41593-019-0560-7
Hohman TJ, Dumitrescu L, Barnes LL, et al. Sex-specific association of apolipoprotein E with cerebrospinal fluid levels of Tau. JAMA Neurol. 2018;75:989-998. doi:10.1001/jamaneurol.2018.0821
Babapour Mofrad R, Tijms BM, Scheltens P, et al. Sex differences in CSF biomarkers vary by Alzheimer disease stage and APOE ε4 genotype. Neurology. 2020;95:e2378-e2388. doi:10.1212/WNL.0000000000010629
Mielke MM, Vemuri P, Rocca WA. Clinical epidemiology of Alzheimer's disease: assessing sex and gender differences. Clin Epidemiol. 2014;6:37-48. doi:10.2147/CLEP.S37929
Zahodne LB, Sharifian N, Kraal AZ, et al. Longitudinal associations between racial discrimination and brain aging among black older adults - Zahodne - 2021 - Alzheimer's & Dementia - Wiley Online Library n.d. https://alz-journals.onlinelibrary.wiley.com/doi/full/10.1002/alz.051948 (accessed May 31, 2022)
Mayeda ER, Glymour MM, Quesenberry CP, Whitmer RA. Inequalities in dementia incidence between six racial and ethnic groups over 14 years. Alzheimers Dement J Alzheimers Assoc. 2016;12:216-224. doi:10.1016/j.jalz.2015.12.007
Tang MX, Cross P, Andrews H, et al. Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan. Neurology. 2001;56:49-56. doi:10.1212/wnl.56.1.49
Manly JJ, Schupf N, Tang M-X, Stern Y. Cognitive decline and literacy among ethnically diverse elders. J Geriatr Psychiatry Neurol. 2005;18:213-217. doi:10.1177/0891988705281868
Steenland K, Goldstein FC, Levey A, Wharton W. A meta-analysis of Alzheimer's disease incidence and prevalence comparing African-Americans and Caucasians. J Alzheimers Dis JAD. 2016;50:71-76. doi:10.3233/JAD-150778
Wharton W, Goldstein FC, Zhao L, Steenland K, Levey AI, Hajjar I. Modulation of renin-angiotensin system may slow conversion from mild cognitive umpairment to Alzheimer's disease. J Am Geriatr Soc. 2015;63:1749-1756. doi:10.1111/jgs.13627
Malik M, Parikh I, Vasquez JB, et al. Genetics ignite focus on microglial inflammation in Alzheimer's disease. Mol Neurodegener. 2015;10:52. doi:10.1186/s13024-015-0048-1
Song W, Hooli B, Mullin K, et al. Alzheimer's disease-associated TREM2 variants exhibit either decreased or increased ligand-dependent activation. Alzheimers Dement J Alzheimers Assoc. 2017;13:381-387. doi:10.1016/j.jalz.2016.07.004
Andreone BJ, Przybyla L, Llapashtica C, et al. Alzheimer's-associated PLCγ2 is a signaling node required for both TREM2 function and the inflammatory response in human microglia. Nat Neurosci. 2020;23:927-938. doi:10.1038/s41593-020-0650-6
Wang S, Mustafa M, Yuede CM, et al. Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer's disease model. J Exp Med. 2020;217:e20200785. doi:10.1084/jem.20200785
Lewcock JW, Schlepckow K, Di Paolo G, Tahirovic S, Monroe KM, Haass C. Emerging microglia biology defines novel therapeutic approaches for Alzheimer's disease. Neuron. 2020;108:801-821. doi:10.1016/j.neuron.2020.09.029
Schlepckow K, Monroe KM, Kleinberger G, et al. Enhancing protective microglial activities with a dual function TREM2 antibody to the stalk region. EMBO Mol Med. 2020;12:e11227. doi:10.15252/emmm.201911227
Meilandt WJ, Ngu H, Gogineni A, et al. Trem2 deletion reduces late-stage amyloid plaque accumulation, elevates the Aβ42:aβ40 ratio, and exacerbates axonal dystrophy and dendritic spine loss in the PS2APP Alzheimer's Mouse Model. J Neurosci Off J Soc Neurosci. 2020;40:1956-1974. doi:10.1523/JNEUROSCI.1871-19.2019
Joshi P, Riffel F, Kumar S, et al. TREM2 modulates differential deposition of modified and non-modified Aβ species in extracellular plaques and intraneuronal deposits. Acta Neuropathol Commun. 2021;9:168. doi:10.1186/s40478-021-01263-x
Price BR, Sudduth TL, Weekman EM, et al. Therapeutic Trem2 activation ameliorates amyloid-beta deposition and improves cognition in the 5XFAD model of amyloid deposition. J Neuroinflammation. 2020;17:238. doi:10.1186/s12974-020-01915-0
Cignarella F, Filipello F, Bollman B, et al. TREM2 activation on microglia promotes myelin debris clearance and remyelination in a model of multiple sclerosis. Acta Neuropathol (Berl). 2020;140:513-534. doi:10.1007/s00401-020-02193-z
Filipello F, Goldsbury C, You SF, Locca A, Karch CM, Piccio L. Soluble TREM2: innocent bystander or active player in neurological diseases? Neurobiol Dis. 2022;165:105630. doi:10.1016/j.nbd.2022.105630
Arboleda-Velasquez JF, Lopera F, O'Hare M, et al. Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report. Nat Med. 2019;25:1680-1983. doi:10.1038/s41591-019-0611-3
Reiman EM, Arboleda-Velasquez JF, Quiroz YT, et al. Exceptionally low likelihood of Alzheimer's dementia in APOE2 homozygotes from a 5,000-person neuropathological study. Nat Commun. 2020;11:667. doi:10.1038/s41467-019-14279-8
Monsell SE, Kukull WA, Roher AE, et al. Characterizing apolipoprotein E ε4 carriers and noncarriers with the clinical diagnosis of mild to moderate Alzheimer dementia and minimal β-amyloid peptide plaques. JAMA Neurol. 2015;72:1124-1131. doi:10.1001/jamaneurol.2015.1721
Reiman EM, Chen K, Liu X, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A. 2009;106:6820-6825. doi:10.1073/pnas.0900345106
Jansen WJ, Ossenkoppele R, Knol DL, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313:1924-1938. doi:10.1001/jama.2015.4668
Ekert JO, Gould RL, Reynolds G, Howard RJ. TNF alpha inhibitors in Alzheimer's disease: a systematic review. Int J Geriatr Psychiatry. 2018;33:688-694. doi:10.1002/gps.4871
McAlpine FE, Tansey MG. Neuroinflammation and tumor necrosis factor signaling in the pathophysiology of Alzheimer's disease. J Inflamm Res. 2008;1:29-39. doi:10.2147/jir.s4397
Clark I, Atwood C, Bowen R, Paz-Filho G, Vissel B. Tumor necrosis factor-induced cerebral insulin resistance in Alzheimer's disease links numerous treatment rationales. Pharmacol Rev. 2012;64:1004-1026. doi:10.1124/pr.112.005850
De Sousa Rodrigues ME, Houser MC, Walker DI, et al. Targeting soluble tumor necrosis factor as a potential intervention to lower risk for late-onset Alzheimer's disease associated with obesity, metabolic syndrome, and type 2 diabetes. Alzheimers Res Ther. 2019;12:1. doi:10.1186/s13195-019-0546-4
